Stockscreener 앱 받기
4.95
2.92%
0.15
Kodiak Sciences Inc 주식(KOD)의 최신 뉴스
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatilit - GuruFocus
CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics - The Malaysian Reserve
Breakthrough Eye Disease Platform: Kodiak Sciences Reveals 7 Major Advances at ARVO 2025 - Stock Titan
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases - Yahoo Finance
Wet Age-Related Macular Degeneration Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight - Barchart.com
Kodiak Sciences Inc [KOD] Shares Rise 9.62 % on Wednesday - knoxdaily.com
A year in review: Kodiak Sciences Inc (KOD)’s performance in the last year - uspostnews.com
Insider’s View: Deciphering Kodiak Sciences Inc (KOD)’s Financial Health Through Ratios - DWinneX
April 2025's Promising Penny Stocks - Yahoo
AMKR Shares Experience Decline in Value - knoxdaily.com
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
Why Coffee Prices Remain Volatile - The Globe and Mail
Prudential Financial Inc. Sells 65,400 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wet Age-Related Macular Degeneration Therapeutics Market Size - openPR.com
Sei Investments Co. Sells 69,599 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences stock hits 52-week low at $2.15 - Investing.com India
HC Wainwright Comments on Kodiak Sciences Q2 Earnings - Defense World
HC Wainwright Forecasts Kodiak Sciences Q1 Earnings - Defense World
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) - Yahoo Finance
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target By Investing.com - Investing.com South Africa
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target - Investing.com
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Charles Schwab Investment Management Inc. Sells 6,758 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Advances Retinal Therapies with Promising Pipeline - TipRanks
Kodiak Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KODIAK SCIENCES Earnings Results: $KOD Reports Quarterly Earnings - Nasdaq
Kodiak Sciences Cuts Losses by 26%, Advances Two Phase 3 Trials with $168M War Chest - Stock Titan
Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5? - Insider Monkey
Diabetic Macular Edema Pipeline 2025: Therapies Under - openPR
Kodiak Sciences Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Critical Contrast: Metagenomi (NASDAQ:MGX) & Kodiak Sciences (NASDAQ:KOD) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Retinal Vein Occlusion Clinical and Non-Clinical Studies, Key - openPR
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate - MSN
Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Why Palantir (PLTR) Stock Is Up Today - The Globe and Mail
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy - Marketscreener.com
Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial - TipRanks
KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan
CDC To Study Vaccines and Autism, Despite Much Research Showing No Link - 69News WFMZ-TV
Clinical Trial Success: Kodiak Enrolls 250+ Patients for Novel Diabetic Eye Drug - Stock Titan
Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Yahoo Finance
Kodiak Sciences’ Anti-VEGF Could Win Nicely On Retinal Disorders (NASDAQ:KOD) - Seeking Alpha
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise - The Globe and Mail
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Large Increase in Short Interest - MarketBeat
Elisa Oyj (OTCMKTS:ELMUF) Short Interest Update - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Significant Growth in Short Interest - Defense World
0.03%
0.49%
자본화:
|
볼륨(24시간):